Arrhythmia As the Presenting Symptom of a Primary Cardiac Lymphoplasmacytic Lymphoma

Overview

Journal HeartRhythm Case Rep

Date 2024 May 27

PMID 38799592

Authors

Sumair Ozair

Gene Gerlach

Neha Patil

Karthik Venkatesh Prasad

Affiliations

Soon will be listed here.

References

Binder J, Pfleger S, Schwarz S . Images in cardiovascular medicine. Right atrial primary cardiac lymphoma presenting with stroke. Circulation. 2004; 110(17):e451-2. DOI: 10.1161/01.CIR.0000146801.57023.65. View

Ceresoli G, Ferreri A, Bucci E, Ripa C, Ponzoni M, Villa E . Primary cardiac lymphoma in immunocompetent patients: diagnostic and therapeutic management. Cancer. 1997; 80(8):1497-506. DOI: 10.1002/(sici)1097-0142(19971015)80:8<1497::aid-cncr18>3.0.co;2-0. View

Lin J . Cardiac lymphoma with first manifestation of recurrent syncope-a case report and literature review. Int Med Case Rep J. 2013; 3:1-6. PMC: 3658218. DOI: 10.2147/imcrj.s9269. View

Tai C, Wang W, Chung M, Liu J, Chiang C, Yen C . Complete atrio-ventricular block as a major clinical presentation of the primary cardiac lymphoma: a case report. Jpn J Clin Oncol. 2001; 31(5):217-20. DOI: 10.1093/jjco/hye046. View

Mugge A, Daniel W, Haverich A, LICHTLEN P . Diagnosis of noninfective cardiac mass lesions by two-dimensional echocardiography. Comparison of the transthoracic and transesophageal approaches. Circulation. 1991; 83(1):70-8. DOI: 10.1161/01.cir.83.1.70. View

Cheson B, Leoni L . Bendamustine: mechanism of action and clinical data. Clin Adv Hematol Oncol. 2012; 9(8 Suppl 19):1-11. View

Hayes Jr D, Liles D, Sorrell V . An unusual cause of new-onset atrial flutter: primary cardiac lymphoma. South Med J. 2003; 96(8):799-802. DOI: 10.1097/01.SMJ.0000054225.89526.BD. View

Castillo J, Treon S . Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018; 32(5):811-820. DOI: 10.1016/j.hoc.2018.05.008. View

Wiestner A . BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology Am Soc Hematol Educ Program. 2015; 2014(1):125-34. DOI: 10.1182/asheducation-2014.1.125. View

10.

Castillo J, Ghobrial I, Treon S . Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95. DOI: 10.1007/978-3-319-13150-4_7. View

11.

Castillo J, Kanan S, Meid K, Manning R, Hunter Z, Treon S . Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol. 2015; 174(4):645-8. DOI: 10.1111/bjh.13794. View

12.

Rummel M, Al-Batran S, Kim S, Welslau M, Hecker R, Kofahl-Krause D . Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23(15):3383-9. DOI: 10.1200/JCO.2005.08.100. View

13.

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

14.

Rummel M, Niederle N, Maschmeyer G, Banat G, von Grunhagen U, Losem C . Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-10. DOI: 10.1016/S0140-6736(12)61763-2. View